Butantan Institute, a biomedical research centre in Brazil, has developed a potential COVID-19 vaccine and will seek regulatory approval to begin human trials, according to two sources familiar with the matter, Reuters news agency reported on Friday,
The sources said that Butantan plans to test the vaccine, named Butanvac, on 1,800 volunteers over two phases.
This vaccine has been 100% developed in Brazil by an international consortium that also includes Vietnam and Thailand.
Production on a large scale is anticipated to start in May 2021.
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025